Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence

Breast Cancer Research and Treatment

Volumn 126, Issue 3, 2011, Pages 695-703

  Azoulay, Laurent ^a,b   Dell'Aniello, Sophie ^a   Huiart, Laetitia ^c,d   Du Fort, Guillaume Galbaud ^a,b   Suissa, Samy ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c INSTITUT PAOLI CALMETTES   (France)

^d AIX MARSEILLE UNIV   (France)

Author keywords

Breast cancer; CYP2D6 inhibitors; Recurrence; Tamoxifen

Indexed keywords

AMFEBUTAMONE; AMIODARONE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CARVEDILOL; CELECOXIB; CHLORAMPHENICOL; CITALOPRAM; CODEINE; CYTOCHROME P450 2D6 INHIBITOR; CYTOCHROME P450 INHIBITOR; DOXEPIN; DULOXETINE; FLECAINIDE; FLUOXETINE; FLUPHENAZINE; HALOPERIDOL; IMATINIB; METHADONE; METOCLOPRAMIDE; NEFAZODONE; NEUROLEPTIC AGENT; PAROXETINE; PRIMAQUINE; QUINIDINE; RANITIDINE; RISPERIDONE; TAMOXIFEN; TIMOLOL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER RECURRENCE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG COMPETITION; DRUG ELIMINATION; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; TREATMENT DURATION; UNITED KINGDOM;

AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COHORT STUDIES; CYTOCHROME P-450 CYP2D6; FEMALE; GREAT BRITAIN; HUMANS; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; RISK; TAMOXIFEN; TREATMENT OUTCOME;

EID: 79958754972     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1162-y     Document Type: Article

References (34)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-1717
2. Perez EA (2007) Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann Oncol 18(Suppl 8):viii26-viii35
3. Jordan VC (2007) New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer. Steroids 72:829-842 (Pubitemid 47410069)
4. Ingelman-Sundberg M (2005) Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5:6-13 (Pubitemid 40220611)
5. Seruga B, Amir E (2010) Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis. Breast Cancer Res Treat 122:609-617
6. Lacy C, Armstrong L, Goldman M, Lance L (2007) Cytochrome P450 enzymes: substrates, inhibitors, and inducers. In: Lacy C, Armstrong L, Goldman M, Lance L (eds) Drug information handbook, 15th edn. LexiComp Inc., Hudson, pp 1899-1912
7. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P et al (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758-1764 (Pubitemid 38008898)
8. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH et al (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30-39
9. Lehmann D, Nelsen J, Ramanath V, Newman N, Duggan D, Smith A (2004) Lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition. J Clin Pharmacol 44:861-865 (Pubitemid 38971567)
10. Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM et al (2007) The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 101:113-121 (Pubitemid 47555336)
11. Lash TL, Pedersen L, Cronin-Fenton D, Ahern TP, Rosenberg CL, Lunetta KL et al (2008) Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. Br J Cancer 99:616-621
12. Chubak J, Buist DS, Boudreau DM, Rossing MA, Lumley T, Weiss NS (2008) Breast cancer recurrence risk in relation to antidepressant use after diagnosis. Breast Cancer Res Treat 112: 123-132
13. Ahern TP, Pedersen L, Cronin-Fenton DP, Sorensen HT, Lash TL (2009) No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications. Cancer Epidemiol Biomarkers Prev 18:2562-2564
14. Lash TL, Cronin-Fenton D, Ahern TP, Rosenberg CL, Lunetta KL, Silliman RA et al (2010) Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. Acta Oncol 49:305-312
15. Dezentje VO, van Blijderveen NJ, Gelderblom H, Putter H, Van Herk-Sukel MP, Casparie MK et al (2010) Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol 28:2423-2429
16. Siegelmann-Daniel N, Kurnik D, Lomnicky Y, Vesterman-Landes J, Katzir I, Bialik M et al. (2010) Potent CYP2D6 inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen. Breast Cancer Res Treat. doi:10.1007/s10549-010-1008-7
17. Holzman D (2009) Tamoxifen, antidepressants, and CYP2D6: the conundrum continues. J Natl Cancer Inst 101:1370-1371
18. Walley T, Mantgani A (1997) The UK General Practice Research Database. Lancet 350:1097-1099 (Pubitemid 27437871)
19. Garcia Rodriguez LA, Perez GS (1998) Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 45:419-425 (Pubitemid 28227341)
20. Jick H, Jick SS, Derby LE (1991) Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 302:766-768
21. Lawrenson R, Williams T, Farmer R (1999) Clinical information for research; the use of general practice databases. J Public Health Med 21:299-304 (Pubitemid 29446069)
22. Lawrenson R, Todd JC, Leydon GM, Williams TJ, Farmer RD (2000) Validation of the diagnosis of venous thromboembolism in general practice database studies. Br J Clin Pharmacol 49:591-596 (Pubitemid 30326559)
23. Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodriguez LA, Ruigomez A, Meier CR et al (2003) Validity of the general practice research database. Pharmacotherapy 23:686-689 (Pubitemid 36539051)
24. Suissa S (2005) Novel approaches to pharmacoepidemiology study design and statistical analysis. In: Strom B (ed) pharmaco-epidemiology, 4th edn. John Wiley & Sons, Chichester England, pp 811-829
25. Essebag V, Platt RW, Abrahamowicz M, Pilote L (2005) Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Methodol 5:5
26. Essebag V, Genest J Jr, Suissa S, Pilote L (2003) The nested casecontrol study in cardiology. Am Heart J 146:581-590
27. de Vos D, Slee PH, Stevenson D, Briggs RJ (1992) Serum elimination half-life of tamoxifen and its metabolites in patients with advanced breast cancer. Cancer Chemother Pharmacol 31:76-78
28. Brewster DH, Thomson CS, Hole DJ, Black RJ, Stroner PL, Gillis CR (2001) Relation between socioeconomic status and tumour stage in patients with breast, colorectal, ovarian, and lung cancer: results from four national, population based studies. BMJ 322:830-831 (Pubitemid 32291133)
29. Carroll DG, Kelley KW (2009) Use of antidepressants for management of hot flashes. Pharmacotherapy 29:1357-1374
30. Kelly CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI, Austin PC et al (2010) Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 340:c693
31. Decensi A, Robertson C, Viale G, Pigatto F, Johansson H, Kisanga ER et al (2003) A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 95:779-790 (Pubitemid 36798424)
32. Kisanga ER, Gjerde J, Guerrieri-Gonzaga A, Pigatto F, Pesci-Feltri A, Robertson C et al (2004) Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial. Clin Cancer Res 10:2336-2343 (Pubitemid 38445691)
33. Lash TL, Lien EA, Sorensen HT, Hamilton-Dutoit S (2009) Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol 10:825-833
34. Huiart L, Dell'Aniello S, Suissa S (2009) Patterns of use of tamoxifen and aromatase inhibitors: a population-based observational study. J Clin Oncol 27:556